A comparative analysis of SARS-CoV-2 viral load across different altitudes

Esteban Ortiz-Prado1,2,3*, Raul Fernandez-Naranjo3, Jorge Eduardo Vásconez3, Alexander Paolo Vallejo-Janeta1, Diana Morales-Jadan4, Ismar A. Rivera-Olivero1, Tannya Lozada3, Gines Viscor2, Miguel Angel Garcia-Bereguiain1,3 & The UDLA-COVID-19 team4*

SARS-CoV-2 has spread throughout the world, including areas located at high or very high altitudes. There is a debate about the role of high altitude hypoxia on viral transmission, incidence, and COVID-19 related mortality. This is the first comparison of SARS-CoV-2 viral load across elevations ranging from 0 to 4300 m. To describe the SARS-CoV-2 viral load across samples coming from 62 cities located at low, moderate, high, and very high altitudes in Ecuador. An observational analysis of viral loads among nasopharyngeal swap samples coming from a cohort of 4929 patients with a RT-qPCR test positive for SARS-CoV-2. The relationship between high and low altitude only considering our sample of 4929 persons is equal in both cases and not significative (p-value 0.19). In the case of low altitude, adding the sex variable to the analysis, it was possible to find a significative difference between men and women (p-value < 0.05). Considering initially sex and then altitude, it was possible to find a significative difference between high and low altitude for men (p-value 0.05). There is not enough evidence to state that viral load is affected directly by altitude range but adding a new variable as sex in the analysis shows that the presence of new variables influences the relationship of altitude range and viral load. There is no evidence that viral loads (Ct and copies/ml) differ at low or high altitude. Using sex as a co-factor, we found that men have higher viral loads than women at low and moderate altitude locations, while living at high altitude, no differences were found. When Ct values were aggregated by low, moderate, and high viral load, we found no significative differences when sex was excluded from the analysis. We conclude that viral load is not directly affected by altitude, but COVID-19 incidence and mortality are rather affected by socio-demographic and idiosyncratic dynamics.

The COVID-19 pandemic has been one of the most serious public health problems of the last century1. Since its declaration, more than 600 million confirmed cases had been reported worldwide2. While the number of deaths has not yet exceeded 7 million, unofficially, excess deaths have been estimated at more than 20 million worldwide3,4. Ecuador as well as most of the countries in Latin America, were the most affected, especially in the early stages of the outbreak5. For example, Ecuador suffered the most lethal COVID-19 related wave of the pandemic in the first trimester of 2020, reporting more than 700% more deaths per capita than the United Sated of the America on its most critical day6. For example, the USA reported just over 5000 deaths in a single day (1.5 deaths/100,000), Brazil reported 4,300 deaths in a single day (1.9/100,000), and Peru reported just over 700 deaths in a single day (2.4/100,000), but Ecuador reported over 1200 deaths in a single day (6.7/100,000)7.

Since then, certain interrogations remain unsolved concerning viral transmission and the burden of COVID-19 at different altitudes8–10. The role of high altitude exposure on COVID-19 attack rate or SARS-CoV-2 infection has generated controversy and intrigued the scientific community8, nevertheless, there are still various questions surrounding this alleged relationship. One of the reasons behind these unresolved doubts might be due to the fact that most of the countries worldwide have their populations living at low altitudes, while some of the countries that are actually located at high altitude, have no low-altitude towns to compare with, except some Andean and very few Asian countries11. In this sense, classifying high altitude populations is not an easy task. Often, the

---

1One Health Research Group, Faculty of Medicine, Universidad de Las Americas, Calle de los Colimes y Avenida De los Granados, 17013 Quito, Ecuador. 2Department of Cell Biology, Physiology, and Immunology of the Faculty of Biology, Universitat de Barcelona, Barcelona, Spain. 3Facultad de Ciencias de la Salud, Universidad Latina de Costa Rica, San Pedro, Costa Rica. 4Decanato de Investigación y Vinculación, Universidad de Las Americas, Quito, Ecuador. *A list of authors and their affiliations appears at the end of the paper. **email: e.ortizprado@gmail.com
The hypotheses surrounding the role of high altitude on SARS-CoV-2 transmission and the impact of the pandemic in these populations can be classified in three main groups: (1) The physiological and biological role of altitude-adapted organisms in relation to virus transmission or replication (i.e. the role of ACE-2 receptors at high altitude), (2) the epidemiological relationship between sociodemographic factors and COVID-19 incidence and mortality at high altitude (i.e. population density, overcrowding activities or migration) and lastly, (3) the direct or indirect consequences of the environment on virulence or viral transmission (i.e. ozone, UV exposure or cold)9,10,11,13,15,17,20.

From these, the least studied factor has been the possible influence of living at high altitude where hypobaric hypoxia could influence viral transmission or viral replication. In this sense, a suitable indicator would be the evaluation of viral load using the reverse transcription polymerase chain reaction (RT-PCR) test across patients with a positive diagnosis of SARS-CoV-2 infection21,22. Using the number of cycles (Ct) required to detect the presence of the SARS-CoV-2 within a RT-qPCR test have been widely used23.

The aim of this study was to compare SARS-CoV-2 viral load across patients living in different jurisdictions located at low, moderate, high or very high altitudes in Ecuador.

**Methods and data**

**Study design.** An observational, ecological analysis of 4929 patients that tested positive for SARS-CoV-2 infection as part of our COVID-19 detection-campaign across 62 jurisdictions in Ecuador during May 2020 to October 2020 was carried out.

**Setting.** The study was carried out in Ecuador, one of the smallest Latin-American countries, located in the equatorial line and bordering the Pacific Ocean. Ecuador shares borders with Peru and Colombia and its current population is estimated to be 17,577,116 inhabitants. The country has four regions (Coastal Lowlands, The Andean Highlands, The Amazonian Basin, and the Galapagos Islands) organized in 24 provinces and 221 political subdivisions called cantons (cities) with an elevation range from 0 to 4300 m (Fig. 1). The population density in Ecuador is 71 per km² (184 people per mi²), the total land area is 248,360 km² (95,892 mi²), 63% of the population is urban (11,123,641 people in 2020) and the median age in Ecuador is 27.9 years6.

**Population.** The sampling included all persons who voluntarily approached our diagnostic station to have their SARS-CoV-2 viral status during our national SARS-CoV-2 detection countrywide campaign. More than 22,000 subjects were sampled countrywide and from those, 4929 patients tested positive for SARS-CoV-2 infection during this time.

**Data source and variables.** After obtaining the informed consent, an epidemiological data-recollection sheet form was completed, including demographic variables including sex, age, jurisdiction of residence as well as symptomology status were obtained. For nasopharyngeal swabs samples, the Center for Disease Control (CDC) 2019-Novel Coronavirus (2019-nCoV) RT-qPCR Diagnostic Panel was used to identify the presence of SARS-CoV-2. All samples were processed in the BSL2 certified molecular biology laboratory at Universidad de Las Americas.

**RNA Extraction and RT-qPCR for SARS-CoV-2 diagnosis using 2019-nCoV CDC kit.** The samples were processed in the BSL2 certified molecular biology laboratory at Universidad de Las Americas. Nasopharyngeal swabs were collected on 0.5 mL TE pH 8 buffer for SARS-CoV-2 diagnosis by RT-qPCR following an adapted version of the CDC protocol as it has been previously described by our laboratory. Briefly, the CDC RT-qPCR protocol is based on N1 and N2 gene targets to detect SARS-CoV-2 and RNase P gene target as an RNA extraction quality control. Also, negative controls (TE pH 8 buffer) were included as control for carryover contamination, one for each set of RNA extractions, to guarantee that only true positives were reported24–27. The criteria for SARS-CoV-2 positivity were a dual amplification of N1 and N2 with Ct values below 40, or a single amplification of either N1 or N2 with Ct values below 40 by duplicate24–27. For viral loads calculation, Ct values for N1 viral target were used and referred to a calibration curve done with the 2019-nCoV N positive control (IDT, USA), provided at 200.000 genome equivalents/µL; a factor of 200 was applied to convert the viral loads to genome equivalents/µL and then converted to logarithmic scale24–27.
Variables. Data from 4929 samples that tested positive for SARS-CoV-2 infection were included. The information from every patient was categorized by Sex (Female or Male), age (0–100 years), viral load (copies/ml), cycle threshold (Ct) and altitude ranges (0–4300 m). Since several investigations use 2500 m as the elevation threshold to define high altitude, we classified our data as follow: Low altitude (anything below 2500 m) and high altitude (anything above 2500 m). Due to the wide range of altitudes found in Ecuador, we also used the International Society of Mountain Medicine classification as: Low altitude (0–1500 m), moderate altitude (1500–2500 m), high altitude (2500–3500 m) and very high altitude (3500 to 5800 m).

Study and sample Size. From the SARS-CoV-2 detection program, we included only the samples that resulted positive. A total of 4,929 subjects from 62 jurisdictions in Ecuador were analyzed. We used a non-probabilistic convenience sample technique until the desire number of positive samples was achieved. From our data, 43% (n = 2135) came from positive samples from those living in low altitude jurisdictions and 57% (n = 2794) came from those living at high altitude.

Statistical methods. Descriptive and inferential analysis was conducted using the software IBM SPSS Statistics for Windows Version 24.0. Figures and graphs were made using the official R software, an open-source free software environment. Measurements of frequency (counts, absolute and relative percentages), central ten-
The average age for women was 38 years (SD = 18.1) while for men was 38 years (SD = 17.5).

Viral load analysis at low, moderate, high, and very high altitudes. Viral load average at low altitude was 170,054,839,743.98 copies/ml (SD = 7,093,792,305,641.90 copies/ml) and at high altitude was 54,177,678.82 (SD = 1,008,390,937.76 copies/ml), being this difference not significant (p-value of 0.27). When considering sex, women had an average viral load of 143,244,371,554.75 copies/ml (SD = 6,652,794,470,175.70 copies/ml) and men had an average viral load of 6,384,471,198.29 copies/ml (SD = 316,562,541,098.43 copies/ml), being this difference not statistically significant (p-value of 0.31) (Fig. 3).

In the case of Ct cycles, we have applied a simple t-test to determine possible differences across sex and altitude. For high altitude there is not difference in Ct (p-value of 0.95 with women having an average Ct of 30.72 and men a Ct average of 30.75). For low altitude it was possible to determine that Ct values for women was 30.7 and for men 31.3 (Fig. 4).

Viral load at low and high altitude are equal.

H1 Viral load at low and high altitude are different.

A t-test analysis parametric or a Wilcoxon–Mann–Whitney nonparametric tests were used to assess differences when indicated.

The hypotheses used can be explained as:

**H₀** Viral load at low and high altitude are equal.

**H₁** Viral load at low and high altitude are different.

Having a wide range of elevations and other covariates as sex, we also tested the hypothesis:

**H₀** Viral load is equal across all altitude ranges.

**H₁** Viral load depends on other variables.

**Ethical approval.** All participants signed an informed consent to participate freely and voluntarily in this SARS-CoV-2 testing surveillance program. This study is a secondary analysis of the anonymized laboratory results from a previous surveillance testing done in the context of COVID-19 pandemic. Nevertheless, the study was approved by Institutional Review Board from Hospital General San Francisco (Quito) with code CEISH-HGSF-2021-002. All procedures performed in our study were in accordance with the ethical standards of the Minister of Public Health (MoH) and with the Helsinki Declaration and comparable ethical standards.

**Bias.** Sample collection and data analysis were performed by qualified personnel from the Universidad de las Americas in the presence of MoH staff. The analysis and interpretation of the data was done with 2 of the investigators separately to look for discrepancies. Any new findings were reviewed by the entire team and a unanimous decision was made in the event of differences in the results. Despite having 4929 observations in our sample and achieving the necessary number of observations for normality in variables, the results are subject of other approaches like non-parametric tests that can be more accurate than traditional normal tests like t-test. Having more data would be necessary to evaluate the differences across altitude and obtain similar performance that other statistical tests can produce to derive conclusions and insights about viral load and altitude.

**Results**

**General Results.** 4,929 people tested positive for SARS-CoV-2 and from this, 51.3% (n = 2530) were men and 48.7% (n = 2399) were women. 43% (n = 2135) came from the low altitude jurisdictions and 57% (n = 2794) came from high altitude locations. In terms of self-reported symptoms, highlanders have a slightly lower proportion of symptomatic patients (51.2%) versus those tested at lower elevations (52.0%).

**Age and sex differences.** From the total sample of 4,929 patients, the average age was 38 years (SD = 17.76). The average age for women was 38 years (SD = 18.1) while for men was 38 years (SD = 17.5).

In terms of age by elevation categories, we found that at low altitude, men have an average age of 35 years (SD = 17.7) while high altitude 40 years (SD = 17.7). On the other hand, low altitude women have an average age of 34 years (SD = 16.8) while high altitude 41 years (SD = 18.5), being any of these differences, statistically significant (p-value < 0.001 for women across high and low altitude and p-value < 0.0001 for men) Fig. 2.

**Viral load analysis.** The average viral load at low altitude was 170,054,839,743.98 copies/ml (SD = 7,093,792,305,641.90 copies/ml) and at high altitude was 54,177,678.82 (SD = 1,008,390,937.76 copies/ml), being this difference not significant (p-value of 0.27). When considering sex, women had an average viral load of 143,244,371,554.75 copies/ml (SD = 6,652,794,470,175.70 copies/ml) and men had an average viral load of 6,384,471,198.29 copies/ml (SD = 316,562,541,098.43 copies/ml), being this difference not statistically significant (p-value of 0.31) Fig. 3.

In the case of Ct cycles, we have applied a simple t-test to determine possible differences across sex and altitude. For high altitude there is not difference in Ct (p-value of 0.95 with women having an average Ct of 30.72 and men a Ct average of 30.75). For low altitude it was possible to determine that Ct values for women was 30.7 and for men 31.3 (Fig. 4).

The hypotheses used can be explained as:

**H₀** Viral load at low and high altitude are equal.

**H₁** Viral load at low and high altitude are different.

A t-test analysis parametric or a Wilcoxon–Mann–Whitney nonparametric tests were used to assess differences when indicated.

The hypotheses used can be explained as:

**H₀** Viral load at low and high altitude are equal.

**H₁** Viral load at low and high altitude are different.

Having a wide range of elevations and other covariates as sex, we also tested the hypothesis:

**H₀** Viral load is equal across all altitude ranges.

**H₁** Viral load depends on other variables.
When comparing viral load by sex and according to four altitude categories, we could not find statistically significant differences. In terms of Ct, when sex is included as covariate using altitude range, at least one relationship between low and high altitude can influence on Ct ($p$-value 0.037). Despite other combinations show $p$-values greater than 0.05 displaying same trend as the previous test, the presence of extreme values can be a
Viral load analysis by age groups at low, moderate, high and very high altitudes. There were no statistically significant differences between age groups and altitude after conducting t-test using as reference the age group. Most of p-values are greater than 0.10 showing that differences in viral load for altitude levels are
not present across age groups. Even using altitude levels for comparison in age groups showed no evidence of any difference in viral load for altitudes. The only difference that can be found is the distribution of viral load for young adults compared to the same group of people living at high altitude (Table 1).

Despite this, we found that elderly dwellers living at high altitude have higher viral load than the elderly living at low altitude and those living at high altitude (Fig. 8).

Figure 5. Box plot of viral load composition across altitude range of SARS-CoV-2 test positivity among 4929 tested people.

Figure 6. Box plot of viral load composition across altitude range of SARS-CoV-2 test positivity among 4929 tested people by sex.
After comparing viral loads by category (low viral load, >28, moderate viral load, 18–28; and high viral load Ct < 18), we found that low and moderate viral loads do vary at different altitudes; however, at high altitude, these differences were not observed (Fig. 9).

**Discussion**

Our exploratory results found no significant difference between people living at high altitude and those living at low altitude locations in terms of SARS-CoV-2 viral load. Our reports are the first one available in terms of exploring this issue at different elevations, and according to our results it seems like living at different altitudes might not play any important role in terms of viral load.

In some investigations, the role that hypobaric hypoxia could have on the viability of the SARS-CoV-2 virus has been analyzed. In very few reports it is mentioned that ozone could affect viral viability, humidity could affect transmissibility and ultraviolet rays (UV lights) could eliminate the virus faster than in other locations where there is less UV light exposure than at high altitude.

There are studies that indicate the influence of environmental factors on the virulence of SARS-CoV-2 at high altitude, among which are dry air, sudden changes in temperature, and ultraviolet radiation levels, as far as this

---

**Low, moderate and high viral load using Ct values.** After comparing viral loads by category (low viral load, >28, moderate viral load, 18–28; and high viral load Ct < 18), we found that low and moderate viral loads do vary at different altitudes; however, at high altitude, these differences were not observed (Fig. 9).

**Table 1.** Viral loads by age and altitude range among patients with a positive infection for SARS-CoV-2.

|                | Low | Moderate | High | Very High |
|----------------|-----|----------|------|-----------|
| N              |     |          |      |           |
| Pre school     | 76  | 120,728,727 | 26   | 104,510   |
| School         | 136 | 19,489,756   | 42   | 763,174   |
| Adolescent     | 226 | 76,732,899,123 | 152  | 19,567,249 |
| Young adult    | 186 | 19,098,980,795 | 1311 | 72,289,578 |
| Adult          | 657 | 523,847,629,773 | 946  | 50,326,524 |
| Elderly        | 109 | 26,880,399    | 291  | 19,231,731 |
| Total          | 2044| 102,307,768,096 | 2768 | 27,047,128 |

---

**Figure 7.** Box plot of Ct composition across altitude range of SARS-CoV-2 test positivity among 4929 positive patients.
last factor is known. that ultraviolet light A and B is capable of altering the molecular bonds of DNA and RNA in terms of its effect on SARS-CoV-2 it is believed that it could shorten the half-life of the virus34,35.

Another factor often linked to the transmission of the SARS-CoV-2 virus may be cold weather. Several studies have suggested that the susceptibility of the virus to temperature may be affected by climate36–38. Although cold temperatures have been associated with increased risk to develop some respiratory diseases such as influenza or other respiratory viruses, it is clear that climate has a more important factor influencing people’s behavior39–41. For instance, people who live in places where the climate can be adverse tend to socialize less, stay in smaller

Figure 8. Box plot of viral load composition across age groups and altitude ranges from a sample of 4929 patients with a positive RT-qPCR positive test for SARS-CoV-2 infection.

Figure 9. Viral load comparison among elevation groups.
family or “social pockets”, to remain in-doors more often, thus, have less risk of being part of higher risk transmissibility activities.\textsuperscript{42–44}

Besides viral transmission, it seems likely that high altitude may have an important role in improving the survival of some seriously ill patients who live at high altitudes.\textsuperscript{45} Even with the presence of comorbidities, survival among severely ill COVID-19 patients at high altitude seems to be improved when compared to low altitude patients, probably linked to their adaptation status that might improves oxygenation.\textsuperscript{45,46}

Most of the reports that have described reduced mortality are observational population-based studies rather than individual-based.\textsuperscript{45,46-48} In this sense, on populations but not on individuals. This confers a limitation since important data, such as viral load, have never been measured in high altitude. A recent report by Arias-Reyes et al. 2021, investigated whether the transmission rate of SARS-CoV-2 differs between low and high altitudes.\textsuperscript{49} They found that after using a mathematical SEIR model, the probability of viral transmission is lower at high altitude, concluding that their findings strongly support the hypothesis of decreased SARS-CoV-2 virulence in highlands compared to lowlands.\textsuperscript{49}

Although the available results suggest lower COVID-19 related mortality at high altitudes, lower viral load cannot be attributed as one causal factor. Viral loads difference among low and high altitude dwellers is unlikely, mainly since the idiopathic response of each organism towards viral replication depend on immunological and biological factors more than in environmental or socio-demographic differences.\textsuperscript{45–47}

It is essential to mention that the number of tests performed in different geographic locations may vary, especially in remote rural areas such as those found at high altitudes.\textsuperscript{49} For example, in the early stages of the pandemic, the country was ranked 152 out of 178 in terms of tests performed per capita\textsuperscript{5}; however, during the later stages of the pandemic, although diagnostic capacity improved, we never reached desirable levels or those recommended by the World Health Organization\textsuperscript{44}. In that sense, the positive testing rate (PTR%) was above 5% during most of the outbreaks in Ecuador. For this reason, our viral load testing analysis excluded PTR%, since having an individual result of the amount of virus replicating in each patient confers an exciting approach to the outgoing debate about the impact of high altitude on SARS-CoV-2 replication or virulence.

The question of whether the SARS-CoV-2 viral load among high-altitude dwellers is different from that of low-altitude dwellers remains unresolved, yet our study aimed to dilucidated if any difference in terms of viral load at different altitude ranges exist.

Limitations
We have identified several limitations of our study. The first and most important is that the viral load was not analyzed in relation to the day of symptom onset, therefore it is not possible to calculate correctly when the peak of transmission was reached in one or another person. Second, it was also not possible to control for factors such as immune status or the use of medications that might reduce viral load or decrease immune response. Finally, causal relationship cannot be established with type of study, but our results may be the door for future, better controlled analyses to try to determine whether SARS-CoV-2 viral loads change with altitude.

Conclusions
Being the first to analyze viral load at different altitudes, this study allows us to answer one of the last questions about the debate on altitude and its effect on SARS-CoV-2 virulence. Our results support the theory that although adaptation to hypoxia would seem to protect people from more severe COVID-19, the amount of replicating virus at different altitudes is independent of elevation. Our study demonstrates that viral loads (Ct and copies/ml) do not differ from low, moderate or high altitude. Using sex as a co-factor, we found that men have higher viral loads than women at low and moderate altitude locations, while living at high altitude, no differences were found. When Ct values were aggregated by low, moderate, and high viral load, we found no significant differences when sex was excluded from the analysis. We conclude that viral load is not directly affected by altitude, but COVID-19 incidence and mortality are rather affected by socio-demographic and idiosyncratic dynamics.

Data availability
The datasets generated analyzed during the current study are available in the following repository: https://github.com/covid19ec/DataCharges.

Received: 8 November 2021; Accepted: 14 September 2022
Published online: 13 October 2022

References
1. Ortiz-Prado, E. et al. Clinical, molecular and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn. Microbiol. Infect. Dis. 98, 115094 (2020).
2. Worldometer. Ecuador Data, Population (2021) and Distribution [Internet]. 2021 [cited 2021 May 17]. Available from: https://www.worldometers.info/world-population/ecuador-population/.
3. Fernandez-Naranjo, R. P., Vasconez, E., Simbaña-Rivera, K., Lister, A., Landazuri, S., Ortiz-Prado, E. The world's deadliest outbreak of disease 2019 (COVID-19), a comprehensive literature review. Clin. Microbiol. Infect. 26(2), 115–130 (2020).
4. Beaney, T. et al. Excess mortality: The gold standard in measuring the impact of COVID-19 worldwide?. J. R. Soc. Med. 113(9), 329–334 (2020).
5. Ortiz-Prado, E. et al. Epidemiological, socio-demographic and clinical features of the early phase of the COVID-19 epidemic in Ecuador. PLoS Negl. Trop. Dis. 15(1), e0008958 (2021).
6. Ortiz-Prado, E. & Fernández-Naranjo, R. Impacto de la COVID-19 en el Ecuador: De los datos inexactos a las muertes en exceso. Rev. Ecuat. Neurol. 29(2), 8–11 (2020).
7. Bamgboye, E. L. et al. COIVD-19 pandemic: Is Africa different?. J. Natl. Med. Assoc. 113, 324–335 (2020).
9. Srivastava, A. COVID-19 and air pollution and Meteorology-an intricate relationship: A review. *Chemosphere* **263**, 128297 (2020).
10. Arias-Reyes, C. et al. Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude? *Respir. Physiol. Neurobiol.* **177**(2), 103443 (2020).
11. Otitoloju, A. A., Okafio, I. P., Fasona, M., Bawa-Allah, K. A., Isanbor, C., Onyeka, C. S., et al. COVID-19 pandemic: Examining the faces of spatial differences in the morbidity and mortality in sub-Saharan Africa, Europe and USA. *medRxiv* (2020).
12. Dongwar, D. & Salihu, H. M. COVID-19 pandemic: Marked global disparities in fatalities according to geographic location and universal health care. *Int. J. Matern. Child Health AIDS* **9**(2), 213 (2020).
13. Ortiz-Prado, E. et al. Analysis of excess mortality data at different altitudes during the COVID-19 outbreak in Ecuador. *High Alt. Med. Biol.* **22**, 406–416 (2021).
14. Millet, G. P., Debecque, T., Brocherie, F., Burttschel, M. & Burttschel, J. Altitude and COVID-19: Friend or foe? A narrative review. *Physiol. Rep.* **8**(24), e14615 (2020).
15. Tremblay, J. C. & Ainslie, P. N. Global and country-level estimates of human population at high altitude. *Proc. Natl. Acad. Sci.* https://doi.org/10.1073/pnas.2102463118 (2021).
16. Cano-Pérez, E. et al. Negative correlation between altitude and COVID-19 pandemic in Colombia: A preliminary report. *Am J Trop Med Hyg.* **103**(6), 2347–2349 (2020).
17. Choquenaira-Quispe, C., Saldaña-Bobadilla, V., Ramirez, J. K. Factors involved in low susceptibility to COVID-19: An adaptation of high altitude inhabitants. *Med. Hypotheses* **143**, 110068. https://doi.org/10.1016/j.mehy.2020.110068 (2020).
18. Pun, M., Turner, R., Strazzazzon, G., Brugger, H. & Swenson, E. R. Lower incidence of COVID-19 at high altitude: Facts and confounders. *High Alt. Med. Biol.* **21**(3), 217–222 (2020).
19. Castillo, J., Fresán, U., Trobajo-Sanmartín, C. & Guevara, M. Altitude and SARS-CoV-2 infection in the first pandemic wave in Spain. *Int. J. Environ. Res. Public Health* **18**(5), 2578 (2021).
20. Simbaña-Rivera, K. et al. High-altitude is associated with better short-term survival in critically ill COVID-19 patients admitted to the ICU. *PLoS ONE* **17**(3), e0262423 (2022).
21. Pujadas, E. et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir. Med.* **8**(9), e70 (2020).
22. Freire-Paspuel, B. et al. Cotton-tipped plastic swabs for SARS-CoV-2 RT-qPCR diagnosis to prevent supply shortages. *Front Cell Infect. Microbiol.* **10**, 356 (2020).
23. Kapoor, M., Kalita, D. & Panda, P. K. Cycle threshold values versus reverse transcription-polymerase chain reaction positivity in COVID-19 de-isolation. *Indian J. Med. Microbiol.* **39**(1), 133–135 (2021).
24. CDC. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing (2021) [Internet], 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html.
25. Freire-Paspuel, B. & García-Bereguain, M. A. Clinical performance and analytical sensitivity of three SARS-CoV-2 nucleic acid diagnostic tests. *Am. J. Trop. Med. Hyg.* **104**(4), 1516 (2021).
26. Freire-Paspuel, B. & García-Bereguain, M. A. Analytical and clinical evaluation of “AccuPower SARS-CoV-2 multiplex RT-PCR kit (Bioneer, South Korea)” and “allplex 2019-nCoV Assay (Seegene, South Korea)” for SARS-CoV-2 RT-PCR diagnosis: Korean CDC EAU as a quality control proxy for developing countries. *Front. Cell Infect. Microbiol.* **11**, 630552 (2021).
27. Freire-Paspuel, B. et al. “One health” inspired SARS-CoV-2 surveillance: The Galapagos Islands experience. *One Health* **11**, 100185 (2020).
28. Ortiz-Prado, E. et al. SARS-CoV-2 viral load analysis at low and high altitude: a case study from Ecuador. *Int. J. Environ. Res. Public Health* **19**(13), 7945 (2022).
29. Semple, J. L. & Moore, G. W. K. High levels of ambient ozone (O3) may impact COVID-19 in high altitude mountain environments. *Respir. Physiol. Neurobiol.* **280**, 103487 (2020).
30. Haque, S. E. & Rahman, M. Association between temperature, humidity, and COVID-19 outbreaks in Bangladesh. *Environ. Sci. Policy.* **114**, 253–255 (2020).
31. Srivastava, S., Garg, L., Bansal, A. & Kumar, B. SARS-CoV-2 infection: Physiological and environmental gift factors at high altitude. *Virusdisease* **3**(1), 450–452 (2020).
32. Nicastro, F. et al. Solar UV-B/A radiation is highly effective in inactivating SARS-CoV-2. *Sci. Rep.* **11**(1), 1–11 (2021).
33. Seyer, A. & Sanlidag, T. Solar ultraviolet radiation sensitivity of SARS-CoV-2. *Lancet Microbe.* **1**(1), e8 (2020).
34. Zubieta. Las ventajas de la radiación ultravioleta en el control del coronavirus [Internet]. [cited 2021 Jun 22]. Available from: https://m.larazon.com/sociedad/2020/04/05/las-ventajas-de-la-radiacion-ultravioleta-en-el-control-del-coronavirus-en-la-altura/.
35. Zubieta-Calleja. Extended longevity at high altitude: Benefits of exposure to chronic hypoxia [Internet]. [cited 2021 Jun 22]. Available from: https://www.bledesjournals.org/article.asp?issn=2468-838X;year=2020;volume=2;issue=2;spage=80;epage=90;aulast=Zubieta-Calleja.
36. Sobral, M. F. F., Duarte, G. B., da Penha Sobral, A. I. G., Marinho, M. L. M. & de Souza, M. A. Association between climate variables and global transmission of SARS-CoV-2. *Sci. Total Environ.* **729**, 138997 (2020).
37. Adedokun, K. A., Olaminmoye, A. O., Mustapha, J. O. & Kamoruodeen, R. T. A close look at the biology of SARS-CoV-2, and the potential influence of weather conditions and seasons on COVID-19 case spread. *Infect. Dis. Poverty* **9**(1), 1–5 (2020).
38. Scaletta, N. Distribution of the SARS-CoV-2 pandemic and its monthly forecast based on seasonal climate parameters. *Int. J. Environ. Res. Public Health* **17**(10), 3493 (2020).
39. Van Noort, S. P., Águas, R., Ballesteros, S. & Gomes, M. G. M. The role of weather on the relation between influenza and influenza-like illness. *J. Theor. Biol.* **298**, 131–137 (2012).
40. Ference, R. S., Leonard, J. A. & Stupak, H. D. Physiologic model for seasonal patterns in flu transmission. *Laryngoscope* **130**(2), 309–313 (2020).
41. Chen, T. H., Du, X. L., Chan, W. & Zhang, K. Impacts of cold weather on emergency hospital admission in Texas, 2004–2013. *Environ. Res.* **169**, 139–146 (2019).
42. Medina-Ramon, M. & Schwartz, J. Temperature, temperature extremes, and mortality: A study of acclimatisation and effect modification in 50 US cities. *Occup. Environ. Med.* **64**(12), 827–833 (2007).
43. Saidan, M. N. et al. Estimation of the probable outbreak size of novel coronavirus (COVID-19) in social gathering events and industrial activities. *Int. J. Infect. Dis.* **98**, 321–327 (2020).
44. Huyhn, T. L. D. Does culture matter social distancing under the COVID-19 pandemic?. *Saf. Sci.* **130**, 104872 (2020).
45. Jaramillo, P. R. M., Simbaña-Rivera, K., Silva, J. V. V., Gómez-Barreno, L., Campoverde, A. B. V., Cevallos, J. F. N., et al. High-altitude is associated with better short-term survival in critically ill COVID-19 patients admitted to the ICU. *medRxiv* 2021 Jan 25;2021.01.22.21249811.
46. Collaco, J. M., Aoyama, B. C., Rice, J. L. & McGrath-Morrow, S. A. Influences of environmental exposures on preterm lung disease. *Expert Rev. Respir. Med.* **10**, 1271–1279 (2021).
47. Segovia-Juarez, J., Castagnetto, J. M. & Gonzales, G. F. High altitude reduces infection rate of COVID-19 but not case-fatality rate. *Respir Physiol Neurobiol.* **281**, 103494 (2020).
48. Woolcott, O. O. & Bergman, R. N. Mortality attributed to COVID-19 in high-altitude populations. *High Alt. Med. Biol.* **21**(4), 409–416 (2020).
49. Arias-Reyes, C. et al. Decreased incidence, virus transmission capacity, and severity of COVID-19 at altitude on the American continent. *PLoS ONE* **16**(3), e0237294 (2021).

50. Fajnzylber, J. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat. Commun.* **11**(1), 1–9 (2020).

51. Mahallawi, W. H., Alsamiri, A. D., Dabbour, A. F., Alsaedi, H. & Al-Zalabani, A. H. Association of viral load in SARS-CoV-2 patients with age and gender. *Front. Med.* **8**, 39 (2021).

52. Wu, Y. et al. Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization. *NPJ Biofilms Microbiomes*. 7(1), 1–9 (2021).

53. Torres, I., Sippy, R. & Sacoto, F. Assessing critical gaps in COVID-19 testing capacity: the case of delayed results in Ecuador. *BMC Public Health* **21**(1), 637 (2021).

54. WHO. Rational use of personal protective equipment for coronavirus disease (COVID-19): interim guidance, 27 February 2020. World Health Organization. (2020).

**Author contributions**

E.O.P. was fully responsible for the conceptualization, data recollection and is fully responsible for the content presented in this study. R.F.N. and E.O.P. were responsible for the high altitude analysis and data representation. E.O.P., J.E.V. and M.A.G. contributed with the drafting of the first version of the manuscript. P.V.J., T.L., I.R.O. and D.M.J. were part of the field-sample collection and RT-qPCR analysis in the molecular laboratory at UDLA University. The UDLA-COVID-19 team Consortium was part of the SARS-CoV-2 surveillance program J.D.R., G.G., A.C.S., K.B.J., S.R.P., J.C.L., H.H., P.M.E., E.A.G., M.S.Z., A.M.T. and N.D.Z. were responsible for the RNA Extraction and Quantitative Real-Time PCR-Based Assays, C.L.P., O.L.E., A.B., and D.S.G. were part of the logistic team that allowed us to visit several communities around Ecuador and V.B., D.M.A., I.M.P. and C.D.B. were responsible for sampling some patients during our visits to high altitude locations. M.A.G. and G.V. were important contributors to the discussion around this manuscript. M.A.G. and G.V. critically reviewed the entire manuscript and produced several comments prior to the submission while E.O.P. completed the writing and the final draft of the present study.

**Funding**

This study was funded by Universidad de Las Américas and by Fundación CRISFE (Fondo “Sumar juntos”).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to E.O.-P.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

**The UDLA-COVID-19 team**

Jonathan Dario Rondal4, Genoveva Granda4, Ana Cecilia Santamaria4, Cynthia Lorena Pino4, Oscar Lenin Espinosa4, Angie Buixton4, David Sanchez Grisales4, Karina Beatriz Jimenez4, Vanessa Bastidas4, Dayana Marcela Aguilar4, Ines Maria Paredes4, Christian David Bilvao4, Sebastian Rodriguez Pazmiño4, Juan Carlos Laglaguano4, Henry Herrera4, Pablo Marcelo Espinosa4, Edison Andres Galarraga4, Marlon Steven Zambrano-Mila4, Ana Maria Tito4 & Nelson David Zapata4